| DocumentPRX-BRF-004 | TopicStrategy | Published11 September 2026 | RevisionA |
1.0Summary
Someone is assigned to figure out reimbursement, a consultant is hired, and the company discovers that its largest commercial question has a timeline of its own, one that began years earlier with decisions nobody labeled as market access decisions at the time.
Clearance is a gate. Coding, coverage, and payment run on calendars, and those calendars are indifferent to when you got cleared.
2.0
The calendars run in parallel, and they are slow
New CPT codes move on the AMA's schedule. The CPT Editorial Panel meets three times a year. Category III codes are released twice a year and take effect six months after release. A Category I code approved at a spring Panel meeting is typically payable the January after next, once RUC valuation and CMS rulemaking finish. Miss a submission window and the clock resets by four months, or by a year.
Medicare payment runs on annual rulemaking, with proposed rules in July, final rules in November, and an effective date of January 1. A comment you did not file in the summer is a rate you live with for a year. The New Technology Add-on Payment has its own interaction with FDA timing. Applications are due in the fall for the fiscal year that starts the following October, and they require FDA marketing authorization by a spring cutoff. A clearance that slips from April to June can cost a full fiscal year of add-on payment.
None of these calendars start when you call a consultant. They started when you chose your clinical endpoints.
3.0
Your pivotal study is also your coverage study
FDA clears a device on safety and effectiveness for its intended use. Payers cover a service when it is medically necessary for a defined population, and increasingly when it improves outcomes against the standard of care. Those are different questions, and a study designed only to answer the first often cannot answer the second. The result is the most common failure mode in device commercialization. The device is cleared, launched, and denied as experimental and investigational, with a second study now needed to satisfy criteria the company could have built into the first.
Coding decisions carry the same hidden consequences. A Category III code gets you a billable code quickly, and it also tells payers the technology is emerging, which several treat as grounds for a blanket non-coverage policy. Whether to pursue Category III, and when, is a coverage strategy decision as much as a coding one.
4.0
RAPID closed the door on waiting
Until this spring, a Breakthrough-designated device could pursue transitional Medicare coverage after clearance through TCET. CMS paused TCET in April 2026 and pointed Breakthrough devices at RAPID, which engages with devices at the IDE stage. The practical consequence is blunt. The Medicare pathway built for exactly the kind of novel technology that struggles with coverage is now available only to companies that start on coverage before they are cleared. A company that waits for the FDA letter has already missed it.
5.0
Investors ask before payers do
Reimbursement has moved from a paragraph in the diligence memo to a line in the term sheet conversation. A Series A company whose access story is "we will address reimbursement after clearance" is asking investors to price an unquantified risk, and they do, with a lower valuation or a milestone tranche. A company that arrives with a coding pathway, a payer evidence plan, and a payment estimate has converted the same risk into a plan, which is a different negotiation.
6.0
What starting early means in practice
6.1 Before submission
Get the landscape, which tells you which codes apply or could, what the relevant payers require as evidence, and what the payment ceiling looks like by site of service. Then put payer-relevant endpoints into the pivotal study while the protocol is still open. This is the cheapest market access work you will ever do, and the only window for some of it.
6.2 During FDA review
Work the calendars, meaning code application timing, NTAP or pass-through eligibility against your expected clearance date, and payer policy monitoring so you know who already has a policy on your category and what it says.
6.3 At clearance
Launch with the coverage dossier drafted, the first payer conversations scheduled, and a claims strategy for the coding ambiguity every new device has. Companies that arrive here prepared collect revenue in year one. Companies that start here spend year one learning what the others already knew.
A Vantage landscape costs $8,000 and takes days. A year between clearance and meaningful coverage costs a year of revenue plus the payroll to survive it. Run the landscape before the submission goes in, and let the clinical team read it before the protocol locks.
Praxa is a market access firm for medtech and life sciences companies; every deliverable ships with a verified evidence trail. Questions about how this applies to your product go to ryan@praxa.partners.
7.0Revision history
| Rev | Date | Change |
|---|---|---|
| A | 11 September 2026 | First published |
Talk to us about your pathway
A 30-minute conversation and a fixed quote from the published menu.